Anne K Monroe1, John A Fleishman, Cindy C Voss, Jeanne C Keruly, Ank E Nijhawan, Allison L Agwu, Judith A Aberg, Richard M Rutstein, Richard D Moore, Kelly A Gebo. 1. *Division of General Internal Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD;†Center for Financing, Access, and Cost Trends, Agency for Healthcare Research and Quality, Rockville, MD;‡Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD;§Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX;‖Divisions of Adult and Pediatric Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD;¶Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY; and#Division of General Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.
Abstract
BACKGROUND: Some individuals who appear poorly retained by clinic visit-based retention measures are using antiretroviral therapy (ART) and maintaining viral suppression. We examined whether individuals with a gap in HIV primary care (≥180 days between HIV outpatient clinic visits) obtained ART during that gap after 180 days. SETTING: HIV Research Network data from 5 sites and Medicaid Analytic Extract eligibility and pharmacy data were combined. METHODS: Factors associated with having both an HIV primary care gap and a new (ie, nonrefill) ART prescription during a gap were evaluated with multinomial logistic regression. RESULTS: Of 6892 HIV Research Network patients, 6196 (90%) were linked to Medicaid data, and 4275 had any Medicaid ART prescription. Over half (54%) had occasional gaps in HIV primary care. Women, older people, and those with suppressed viral load were less likely to have a gap. Among those with occasional gaps (n = 2282), 51% received a new ART prescription in a gap. Viral load suppression before gap was associated with receiving a new ART prescription in a gap (odds ratio = 1.91, 95% confidence interval: 1.57 to 2.32), as was number of days in a gap (odds ratio = 1.04, 95% confidence interval: 1.02 to 1.05), and the proportion of months in the gap enrolled in Medicaid. CONCLUSIONS: Medicaid-insured individuals commonly receive ART during gaps in HIV primary care, but almost half do not. Retention measures based on visit frequency data that do not incorporate receipt of ART and/or viral suppression may misclassify individuals who remain suppressed on ART as not retained.
BACKGROUND: Some individuals who appear poorly retained by clinic visit-based retention measures are using antiretroviral therapy (ART) and maintaining viral suppression. We examined whether individuals with a gap in HIV primary care (≥180 days between HIV outpatient clinic visits) obtained ART during that gap after 180 days. SETTING: HIV Research Network data from 5 sites and Medicaid Analytic Extract eligibility and pharmacy data were combined. METHODS: Factors associated with having both an HIV primary care gap and a new (ie, nonrefill) ART prescription during a gap were evaluated with multinomial logistic regression. RESULTS: Of 6892 HIV Research Network patients, 6196 (90%) were linked to Medicaid data, and 4275 had any Medicaid ART prescription. Over half (54%) had occasional gaps in HIV primary care. Women, older people, and those with suppressed viral load were less likely to have a gap. Among those with occasional gaps (n = 2282), 51% received a new ART prescription in a gap. Viral load suppression before gap was associated with receiving a new ART prescription in a gap (odds ratio = 1.91, 95% confidence interval: 1.57 to 2.32), as was number of days in a gap (odds ratio = 1.04, 95% confidence interval: 1.02 to 1.05), and the proportion of months in the gap enrolled in Medicaid. CONCLUSIONS: Medicaid-insured individuals commonly receive ART during gaps in HIV primary care, but almost half do not. Retention measures based on visit frequency data that do not incorporate receipt of ART and/or viral suppression may misclassify individuals who remain suppressed on ART as not retained.
Authors: Baligh R Yehia; Benjamin French; John A Fleishman; Joshua P Metlay; Stephen A Berry; P Todd Korthuis; Allison L Agwu; Kelly A Gebo Journal: J Acquir Immune Defic Syndr Date: 2014-03-01 Impact factor: 3.731
Authors: Edward M Gardner; Margaret P McLees; John F Steiner; Carlos Del Rio; William J Burman Journal: Clin Infect Dis Date: 2011-03-15 Impact factor: 9.079
Authors: April Buscher; Michael Mugavero; Andrew O Westfall; Jeanne Keruly; Richard Moore; Mari-Lynn Drainoni; Meg Sullivan; Tracey E Wilson; Allan Rodriguez; Lisa Metsch; Lytt Gardner; Gary Marks; Faye Malitz; Thomas P Giordano Journal: AIDS Patient Care STDS Date: 2013-07-26 Impact factor: 5.078
Authors: Michael J Mugavero; Andrew O Westfall; Anne Zinski; Jessica Davila; Mari-Lynn Drainoni; Lytt I Gardner; Jeanne C Keruly; Faye Malitz; Gary Marks; Lisa Metsch; Tracey E Wilson; Thomas P Giordano Journal: J Acquir Immune Defic Syndr Date: 2012-12-15 Impact factor: 3.731
Authors: Peter Rebeiro; Keri N Althoff; Kate Buchacz; John Gill; Michael Horberg; Hartmut Krentz; Richard Moore; Timothy R Sterling; John T Brooks; Kelly A Gebo; Robert Hogg; Marina Klein; Jeffrey Martin; Michael Mugavero; Sean Rourke; Michael J Silverberg; Jennifer Thorne; Stephen J Gange Journal: J Acquir Immune Defic Syndr Date: 2013-03-01 Impact factor: 3.731
Authors: Peter F Rebeiro; Alison G Abraham; Michael A Horberg; Keri N Althoff; Baligh R Yehia; Kate Buchacz; Bryan M Lau; Timothy R Sterling; Stephen J Gange Journal: AIDS Patient Care STDS Date: 2017-02-27 Impact factor: 5.078
Authors: Deborah Goldstein; W David Hardy; Anne Monroe; Qingjiang Hou; Rachel Hart; Arpi Terzian Journal: BMC Public Health Date: 2020-04-16 Impact factor: 3.295